Kornimate/medical-research-clean huggingface dataset:
20-valent pneumococcal conjugate vaccine safety and immunogenicity study in pneumococcal vaccine-naïve adults 60 years of age and older in japan, korea, and taiwan

Conditions: Pneumococcal Disease

Summary: a phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in japan, korea, and taiwan


Eligibility criteria:
inclusion criteria: * male or female participants 60 years of age and older at the time of consent. * adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. (for adults 60 through 64 years of age to be enrolled at japan sites: participants must have a preexisting chronic stable disease with an elevated risk for pneumococcal disease.) exclusion criteria: * history of microbiologically proven invasive disease caused by s pneumoniae. * serious chronic disorder, including metastatic malignancy, severe copd requiring supplemental oxygen, end-stage renal disease with or without dialysis, cirrhosis of the liver, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
retinal sensitivity in brvo after anti-vegf therapy

Conditions: Branch Retinal Vein Occlusion

Summary: the efficacy of anti-vascular endothelial growth factor (vegf) therapy for branch retinal vein occlusion (brvo) is shown, but its effect on retinal sensitivity is not fully investigated. the purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with brvo.


Eligibility criteria:
inclusion criteria: * treatment naive patients of branch retinal vein occlusion with visual acuity of less than 1.0 and macular edema of more than 250 micrometers in foveal thickness. exclusion criteria: * patients with history of treatment for branch retinal vein occlusion, possibility of pregnancy, allergy for ranibizumab, intraocular infection, or severe inflammation will be excluded.
effects of nicotinamide riboside on metabolism and vascular function

Conditions: Aging; Lipemia

Summary: the purpose of this study is to determine the effects of nicotinamide riboside (nr) supplementation on metabolism and vascular function following high-fat meal. differences between young (18-35) and older (60-75) adults will be determined.

the purpose of this study is to determine the effects of 7 days of nicotinamide riboside (nr) or placebo supplementation on metabolism and vascular function following high-fat meal. differences between young (18-35) and older (60-75) adults will be determined.

Eligibility criteria:
inclusion criteria: * age 18 to 35 (young) and 60 to 75 (older) * normo- or pre-hypertensive (blood pressure \<140/90 mmhg) * non-smokers * able to give informed consent and participate in all laboratory visits exclusion criteria: * currently taking any medications that could interfere with cardiovascular or metabolic outcomes will be excluded from the study (e.g., beta-blockers) * known metabolic (e.g. type i or type ii diabetes, cardiovascular disease, etc.) or immunologic (e.g. hiv, cancer, autoimmune, etc.) diseases * food allergies to egg, milk, soy or wheat * women who are pregnant or planning to become pregnant during the course of the study, * pacemaker or other implanted device * unwilling to participate in the experimental protocol or blood draws will be excluded

Keywords: postpandial lipemia microvascular
characterization of focal liver lesions by real-time contrast-enhanced ultrasound imaging (ceus)

Conditions: Focal Liver Lesions; Liver Cancer; Liver Cirrhosis

Summary: the conventional sonography is frequently used to detect incidental focal liver lesions because of its availability, innocuity and low cost. nevertheless, sensibility and specificity of conventional sonography does not exceed 70% for tumoral affections. consequently the interest of this practice must be reconsidered by studying its ratio cost/diagnosis contribution. these limitations of conventional sonography have led to the use of other imaging modalities and invasive or costly procedures such as computed tomography (ct), magnetic resonance imaging (mri) or biopsy. the availability of real-time contrast-enhanced ultrasound imaging (ceus) has changed the strategy in the characterization of focal liver lesions, on healthy or cirrhotic liver in a neoplastic context or not, without inconvenience for the patient. the aim of the present study is to evaluate the place of ceus in term of diagnostic relevance and catch of load cost, in the characterization of focal liver lesions detected but not characterized by ct or conventional sonography.


Eligibility criteria:
inclusion criteria: * target focal liver lesion of size lower than 10 cm and higher than 5 mm detected by conventional ultrasonography exclusion criteria: * patients with acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: myocardial infarction, recent coronary artery intervention, acute cardiac failure (within last month), acute endocarditis and prosthetic valves. * pregnant and lactating women

Keywords: focal liver lesions contrast-enhanced ultrasound sonography cirrhosis suspected liver metastases suspected liver cirrhosis
molecular assessment of lymph nodes in patients with resected (stage i to iiia) non-small cell lung cancer

Conditions: Lung Cancer

Summary: this is a prospective study of surgically resected samples and lymph nodes of lung cancer patients. for histopathologically positive lymph nodes from a complete resection, the investigators would like to analyse tumor tissue by allelotyping and comparing these results with those observed in the primary lung tumor to establish a cartography of molecular alteration in resected lung cancer. for non histopathologically positive lymph nodes, the investigators would like to research the presence (or not) of micrometastasis by allele-specific pcr (polymerase chain reaction).

genetic: it is a prospective study during two years with three years for follow-up. no control group is recruited.

Eligibility criteria:
inclusion criteria: * patients with resectable non-small cell lung cancer (stage i to iiia), with a complete resection of the tumor and paired lymph nodes. * informed consent is required. exclusion criteria: * another cancer * chemotherapy before surgical treatment

Keywords: lung cancer patients non-small cell lung cancer molecular marker lymph node completed resected lung cancer samples and paired lymph node resected
congenital hand and upper extremity malformations

Conditions: Congenital Limb Anomaly Nos

Summary: getting the incidence of upper limb anomalies in our department from 2000 to 2020 and classifying them using ifssh classification and omt classification

a retrospective look at the past 20 years illustrated the changes and developments that characterize the world of hand surgery. during these years, old techniques were developed and standardized, new surgical techniques were described, our knowledge improved and illustrated by better classification systems, and new ideas were born that would guide the future of hand surgery. limb deformities are among the most common birth defects in infants. over the past 150 years, many classifications of limb abnormalities based on bone morphology and anatomy have been developed. congenital anomalies of the hand require consistent and reproducible terminology, and it is a universal language that allows discussion of complex clinical entities, treatment indications and outcome comparisons. ideally, the classification of congenital anomalies of the hand will depend on the etiology, giving some indication of the location in the molecular pathway and / or the anatomical location in the developing limb bud where the error occurs and the moment when the fault occurs. the terms should be understandable to geneticists, anatomists, pathologists, and surgeons, and they should allow easy interpretation to parents and, where appropriate, children affected by these conditions. the classification of congenital anomalies of the upper extremity and the important association of these anomalies with systemic disorders and syndromes are described in this study. depending on the classification, examples are given for each class of anomalies.

Eligibility criteria:
inclusion criteria: - all patients with congenital upper limb anomalies in last 20 years in assiut university hospital. exclusion criteria: * conditions that were considered to be difficult to correctly classify because of late presentation, a large span of clinical presentation, extremely rare conditions, and conditions difficult to differentiate from traumatic conditions were excluded (ie, congenital radial head dislocation, congenital tumorous conditions, marfan syndrome)

Keywords: congenital upper limb anomalies
ai-generated whatsapp reminders vs. no reminders: impact on oral health in young adults

Conditions: White Spot Lesions; Dental Plaque; Oral Hygiene, Oral Health

Summary: this randomized controlled trial aims to evaluate the effectiveness of artificial intelligence-generated whatsapp reminders on improving oral hygiene practices among individuals aged 20-40 years visiting the periodontal clinic at el-qasr el-ainy dental hospital. participants will be randomly assigned to either receive health education followed by ai-generated whatsapp reminders over a 3-month period or to a control group receiving health education only. the primary outcome is the presence of white spot lesions, assessed using the modified gorelick white spot lesion (wsl) index. secondary outcomes include the presence of dental plaque, measured by the plaque index (pi). this study seeks to determine whether ai-generated reminders can enhance oral hygiene adherence compared to standard health education alone.


Eligibility criteria:
inclusion criteria: * received a non-surgical periodontal treatment and oral hygiene instructions. * own a smartphone with whatsapp installed. * willing and able to provide informed consent to participate in the study. exclusion criteria: * individuals with pre-existing oral health conditions requiring specialized care. * patients who received surgical periodontal interventions. * participation in another oral health or diet-related study. * individuals who do not use whatsapp or are unwilling to receive messages through the platform.

Keywords: oral hygiene reminders
comparison of generic and original formulation of clopidogrel

Conditions: Coronary Heart Disease; Percutaneous Coronary Intervention

Summary: clopidogrel is essential for the prevention of vascular events in patients after percutaneous coronary interventions (pci). most of our current knowledge with clopidogrel originates from the clinical investigations that had used plavix®/iscover® from sanofi-aventis as the original formulation of clopidogrel-bisulphate. however, as the patency of plavix® has expired in november 2009 in hungary, several generic clopidogrel have been introduced to the market. some of the generics are using the original bisulphate formulation, while others are with besylate salt of clopidogrel. despite the differences in the clopidogrel-salts, the different carriers might also modulate the pharmacokinetic/pharmacodynamic profile of each drug. as the consequences of the impaired antiplatelet potency might be devastating, including stent thrombosis, the investigators sought to compare generic clopidogrel to the original blister by different assays of platelet aggregation.

clopidogrel is essential for the prevention of vascular events in patients after percutaneous coronary interventions (pci). most of our current knowledge with clopidogrel originates from the clinical investigations that had used plavix®/iscover® from sanofi-aventis as the original formulation of clopidogrel-bisulphate. however, as the patency of plavix® has expired in november 2009 in hungary, several generic clopidogrel have been introduced to the market. some of the generics are using the original bisulphate formulation, while others are with besylate salt of clopidogrel. despite the differences in the clopidogrel-salts, the different carriers might also modulate the pharmacokinetic/pharmacodynamic profile of each drug. as the consequences of the impaired antiplatelet potency might be devastating, including stent thrombosis, the investigators sought to compare generic clopidogrel to the original blister by different assays of platelet aggregation. in a prospective, cross-over, open-label, unblinded study the investigators aim to compare platelet activation and aggregation between plavix® and generic clopidogrel.

Eligibility criteria:
inclusion criteria: * patients in the maintenance phase of pci receiving 1x75 mg clopidogrel and 1x100 mg aspirin * no planned interruption of the antiplatelet therapy in the next 1 month * informed consent exclusion criteria: * oral anticoagulant therapy * contraindication for aspirin or clopidogrel * planned interruption of antiplatelet therapy in the next month

Keywords: platelet aggregation generic clopidogrel comparison vasp-pri
a clinical investigation of the m2a- taper™ hip system

Conditions: Non-inflammatory Degenerative Joint Disease; Osteoarthritis; Avascular Necrosis

Summary: the purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the m2a- taper™ hip system


Eligibility criteria:
inclusion criteria: * patients having primary cemented or cementless total hip replacement for non-inflammatory degenerative joint disease (nidjd), or any of its composite diagnoses of: 1. osteoarthritis, 2. avascular necrosis, 3. traumatic arthritis, 4. subcapital fracture, 5. legg perthes, 6. slipped capital epiphysis, 7. fracture of the pelvis, 8. diastrophic variant * patients with full skeletal maturity. * patients undergoing unilateral total hip arthroplasty or bilateral total hip arthroplasty, either staged or simultaneously. * patients of all races and gender. * patients who are able to follow postoperative care instructions. * patients who are able and willing to return for follow-up evaluations. * patients have a preoperative total harris hip score less than 70 with at least moderate pain. exclusion criteria * patients diagnosed with inflammatory degenerative arthritis (idjd) to include the following composite diagnoses: rheumatoid arthritis, systemic lupus erythematous, pigmented villonodular synovitis, juvenile rheumatoid arthritis and other arthritic processes of inflammatory or autoimmune etiology. * patients less than 18 years. * patients with the presence of a previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the hip joint to be operated. * patients with previous girdlestone procedures. * patients with above the knee amputation of the contralateral and/or ipsilateral leg. * patients with osteoporosis, or marked bone loss which would preclude proper fixation of the prosthesis. * patients who are pregnant. * patients with an active or suspected infection in or around the hip. * patients with parkinson's disease. * patients with vascular insufficiency, muscular atrophy, or neuromuscular disease in the affected limb. * patients with severe instability or deformity of the ligaments and/or surrounding soft tissue which would prelude stability of the prosthesis. * patients with a highly communicable disease or diseases that may limit follow-up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis, neoplastic disease, etc.). * patients unwilling or unable to comply with a rehabilitation program for a cemented or cementless total hip replacement or who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol. * patients with previous hip surgery or conditions that may interfere with the total hip replacement's survival or outcome, e.g., paget's disease, charcot's disease, severe osteoporosis compromising bone stock (dorr type c bone). * patients who qualify for inclusion in the study, but refuse consent to participate in the study. * patients with a "fused" hip. * patients who have had a total hip arthroplasty on the contralateral hip within the last year.

Keywords: hip arthroplasty
phase 2 safety and efficacy study of daptomycin in complicated skin and skin structure infections

Conditions: Soft Tissue Infections

Summary: multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of hdsd daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- ssp for 7-14 days) in patients with csssi due to gram-positive bacteria. patients will be randomized on a 1:1 basis to receive either daptomycin 10 mg/kg i.v. q24h for 4 days or vancomycin 1 g. q12h for up to 14 days.

multicenter, randomized (1:1), semi-single blind study comparing the safety and efficacy of hdsd daptomycin (10 mg/kg q24h for 4 days) with that of comparator (vancomycin +/- ssp for 7-14 days) in patients with csssi due to gram-positive bacteria. patients will be randomized on a 1:1 basis to receive either daptomycin 10 mg/kg i.v. q24h for 4 days or vancomycin 1 g. q12h for up to 14 days. the main criteria for evaluation will be: * efficacy * safety * microbiologic eradication

Eligibility criteria:
inclusion criteria: 1. informed consent obtained 2. male or female ≥18 years of age 3. if female of childbearing potential, willing to practice reliable birth control measures and documented negative pregnancy test 4. skin and skin structure infections of a complicated nature that require intravenous antibiotic treatment 5. gram-positive infecting pathogen 6. physician determination that vancomycin would be the initial treatment of choice 7. at least three clinical signs and symptoms associated with the csssi: * pain; * tenderness to palpation; * elevated temperature; * elevated white blood count; * swelling and/or induration; * erythema (\>1 cm beyond edge of wound or abscess); * pus formation; 8. creatinine clearance of ≥50 ml/min. exclusion criteria: 1. mssa 2. known or suspected bacteremia, osteomyelitis, or endocarditis 3. primary study infection of an uncomplicated nature such as furuncles, simple abscesses, cellulitis not requiring i.v., perirectal abscess, hidradenitis suppurativa, third degree burn infections or other minor infections; 4. conditions where required surgery (in and of itself) constitutes curative treatment of the infection (e.g., amputation); 5. necrotizing infections or concomitant gangrene; 6. myositis with or without skin and skin structure infections; 7. hemodialysis or peritoneal dialysis; 8. bmi ≥40 kg/m2; 9. previous antibiotics exceeding 24 hours within the 48 hours prior to the first dose of study drug 10. patients admitted for rhabdomyolysis including drug overdose 11. neutropenic patients with absolute neutrophil count ≤500 cells/mm3 12. known hiv-infected patients with cd4 count ≤200 cells/ mm3; 13. baseline cpk values ≥2 x uln (upper limit of normal); 14. has received an investigational drug within 30 days of study entry; 15. known to be allergic or intolerant to study medications; 16. unlikely to comply with study procedures 17. is expected to receive hmg coa reductase inhibitors from enrollment through end of treatment

Keywords: csssi mrsa
comparison of propioceptive neuromuscular facilitation vs balance exercise along with conventional therapy for balance and gait in chronic parkinson's patient

Conditions: Parkinson

Summary: to determine the effect of proprioceptive neuromuscular facilitation vs balance exercise along with conventional therapy for balance and gait in chronic parkinson's patients.


Eligibility criteria:
inclusion criteria: * chronic parkinson's patients.(34) * patients from both gender around the age of 45-65.(35) * patient with a score of 42 above on the berg balance scale.(29) * patient with good cognitive function minimum score of 20 or more on mini-mental status examination scale (mmse).(36) exclusion criteria: * patients with a history of recurrent stroke.(37) * patient with peripheral vascular disease.(38) * patient with fracture or dislocation of lower limb.(39) * patient with peripheral nerve injury.(40) * patient with skin discoloration, skin ulcers, and skin allergy.(41)
the effects of frequent follow up on compliance in patients receiving pap therapy due to osa (pap: positive airway pressure, osa: obstructive sleep apnea )

Conditions: Patient Compliance; Sleep Disorder; Obstructive Sleep Apnea of Adult

Summary: the investigators planned to investigate the effect of close monitoring on compliance and the factors affecting compliance among patients receiving pap treatment due to osa.this study was a single-center, prospective, randomized, controlled study approved by the hospital's ethics committee.one hundred twenty-eight patients were randomized as group one or two as group 1 is the study and group 2 is the control group. the first group was called by phone on the 15th day to ask if there were any complaints or problems with the device. sequentially, they were called for controls at the end of the first, third, and sixth months. the second group was accepted as the control group, following our clinic's standard procedure in the first and sixth months. the patients who came to the control were asked if there were any problems with the device and any difficulties in use, and they were again informed about the devices and masks.


Eligibility criteria:
inclusion criteria:, .newly diagnosed osa with psg , and underwent pap titration exclusion criteria: . unfollowed patients